Skip to content
Companies

Promaxo

Office-based MRI for guided prostate biopsy

Raised to date

$26.8M

of $28.8M offered across 1 Form D filing

Still open
$1.9M
Investors
118
Last filed
Mar 30, 2026

About

Promaxo builds a compact, single-sided, low-field MRI system designed to sit inside a urologist's office rather than a hospital imaging suite. The platform is FDA 510(k)-cleared for MRI-guided prostate biopsy and combines imaging, AI-assisted lesion identification, and robotic needle guidance in one machine. Operating at roughly 58-74 mT with a limited fringe field, it installs without the shielding and facility upgrades a conventional scanner requires. The company was founded in 2016 and is backed by a portfolio of over 200 patents.

A single-sided, open-architecture, low-field MRI small enough to install in a physician's office, letting urologists image and perform MR-guided prostate biopsies at the point of care instead of referring patients out to a hospital scanner.

Funding

  • EquityFiled Mar 30, 2026Form D
    $26.8M/ $28.8M

Product

Promaxo MRI System

Medical imaging system

An office-based, single-sided, low-field open MRI platform cleared by the FDA under 510(k) for MRI-guided prostate biopsy, integrating imaging, AI-driven insights and robotic guidance into one compact machine.

  • FDA 510(k) cleared for MRI-guided prostate biopsy
  • Single-sided, open architecture design
  • Low field strength of approximately 58-74 mT

Built for

Urology practices, ambulatory surgery centers and hospitals performing prostate cancer diagnosis and image-guided biopsy

People on file